Spinocerebellar Ataxia Type 6 (Sca6) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Spinocerebellar Ataxia type 6 (SCA6) is a rare, autosomal dominant, late-onset neurodegenerative disease characterized by slowly progressive cerebellar ataxia, dysarthria, and nystagmus. It is caused by a CAG trinucleotide repeat expansion in the CACNA1A gene on chromosome 19p13.13, which encodes the alpha-1A subunit of P/Q-type voltage-gated calcium channels (Cav2.1). SCA6 is unique among polyglutamine diseases in that the affected protein is a voltage-gated calcium channel subunit, making it simultaneously a channelopathy and a polyglutamine disorder[1](#1). [@cerebellar]
SCA6 is one of over 40 genetically distinct subtypes of [Spinocerebellar Ataxia](/diseases/spinocerebellar-ataxia). It has a global prevalence of less than 1 per 100,000 individuals, with the highest frequency in Japan where it accounts for up to 31% of all autosomal dominant cerebellar ataxias[2](#1). The disease typically manifests between ages 43 and 52, with a range from 19 to 73 years, and is generally compatible with a normal lifespan, distinguishing it from many other SCAs[3](#1). [@identification]
Spinocerebellar Ataxia Type 6 (Sca6) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Spinocerebellar Ataxia type 6 (SCA6) is a rare, autosomal dominant, late-onset neurodegenerative disease characterized by slowly progressive cerebellar ataxia, dysarthria, and nystagmus. It is caused by a CAG trinucleotide repeat expansion in the CACNA1A gene on chromosome 19p13.13, which encodes the alpha-1A subunit of P/Q-type voltage-gated calcium channels (Cav2.1). SCA6 is unique among polyglutamine diseases in that the affected protein is a voltage-gated calcium channel subunit, making it simultaneously a channelopathy and a polyglutamine disorder[1](#1). [@cerebellar]
SCA6 is one of over 40 genetically distinct subtypes of [Spinocerebellar Ataxia](/diseases/spinocerebellar-ataxia). It has a global prevalence of less than 1 per 100,000 individuals, with the highest frequency in Japan where it accounts for up to 31% of all autosomal dominant cerebellar ataxias[2](#1). The disease typically manifests between ages 43 and 52, with a range from 19 to 73 years, and is generally compatible with a normal lifespan, distinguishing it from many other SCAs[3](#1). [@identification]
SCA6 is considered the prototype of a "pure" cerebellar ataxia with minimal extra-cerebellar involvement. The neuropathology reveals selective degeneration of [Purkinje cells](/cell-types/purkinje-cells) in the [cerebellum](/brain-regions/cerebellum), particularly in the cerebellar vermis, with relative preservation of other brain structures[4](#1). [@dietary]
SCA6 follows an autosomal dominant inheritance pattern with essentially complete penetrance[1](#1): [@retinal]
| Allele Type | CAG Repeat Count | Significance | [^6]
|---|---|---| [^7]
| Normal | 4-18 repeats | Non-pathogenic | [^8]
| Intermediate/Uncertain | 19-20 repeats | Uncertain penetrance | [^9]
| Pathogenic (full penetrance) | 20-33 repeats | Disease-causing | [^10]
| Most common pathogenic allele | 22 repeats | Typical expansion | [^11]
Unlike most other polyglutamine disorders such as [Huntington's disease](/mechanisms/huntington-pathway) or SCA1, SCA6 does not show significant intergenerational instability of the repeat. The CAG repeat expansions are relatively stable during transmission, so anticipation (earlier onset in successive generations) is generally not observed[5](#1). [^12]
The CACNA1A gene encodes two distinct proteins through a bicistronic mechanism discovered in 2013[6](#1): [^13]
The polyglutamine tract expanded in SCA6 resides within the alpha-1ACT protein. When expanded, alpha-1ACT loses its transcription factor function and gains toxic properties[6](#1). [^14]
SCA6 is one of four allelic disorders caused by mutations in CACNA1A: [^15]
| Disorder | Mutation Type | Key Features | [^16]
|---|---|---| [^17]
| SCA6 | CAG repeat expansion (20-33) | Late-onset progressive cerebellar ataxia | [^18]
| Episodic Ataxia Type 2 (EA2) | Loss-of-function mutations | Episodic ataxia; responds to acetazolamide |
| Familial Hemiplegic Migraine Type 1 (FHM1) | Gain-of-function missense | Hemiplegic migraine with or without ataxia |
| CACNA1A epileptic encephalopathy | Haploinsufficiency | Cognitive impairment, epilepsy, mild cerebellar signs |
SCA6 pathophysiology is multifaceted, involving at least three interrelated mechanisms[7](#1):
P/Q-type voltage-gated calcium channels are particularly abundant in cerebellar Purkinje cells and granule cells. The polyglutamine expansion in SCA6[8](#1):
Despite the relatively small polyglutamine expansion (20-33 repeats, the smallest of any polyQ disorder), SCA6 exhibits toxic [protein aggregation](/mechanisms/protein-aggregation)[4](#1):
The expanded alpha-1ACT protein fails to properly regulate expression of genes involved in Purkinje cell development and maintenance, contributing to progressive [neurodegeneration](/diseases/neurodegeneration). Recent research has also identified impaired [mitophagy](/mechanisms/mitophagy) in SCA6 Purkinje cells and reduced [BDNF](/proteins/bdnf-protein) signaling[9](#1).
Postmortem studies reveal:
SCA6 presents as a slowly progressive, predominantly cerebellar syndrome[3](#1):
Initial symptoms (in approximately 90% of cases): Gait unsteadiness, stumbling, and imbalance. In approximately 10%, dysarthria is the first symptom.
Core clinical features:
Oculomotor dysfunction is a hallmark of SCA6:
SCA6 progresses more slowly than SCA1, SCA2, or [SCA3](/genes/sca3). The annual SARA (Scale for the Assessment and Rating of Ataxia) score increase is approximately 0.81 points per year. Most patients require wheelchair assistance by their sixties[10](#1).
SCA6 should be suspected in individuals with adult-onset, slowly progressive cerebellar ataxia with prominent dysarthria and nystagmus (especially downbeat nystagmus), particularly with autosomal dominant family history.
Molecular genetic testing is the gold standard: PCR-based determination of CAG repeats in the CACNA1A gene. Finding 20 or more CAG repeats confirms the diagnosis[11](#1).
[MRI](/diagnostics/mri-neuroimaging) reveals essentially pure cerebellar atrophy, particularly of the cerebellar vermis, with the brainstem and cerebral hemispheres typically spared.
There is currently no disease-modifying therapy or cure for SCA6. Management is symptomatic and supportive[12](#1).
SCA6 prevalence varies significantly by geography due to founder effects[15](#1):
| Region | SCA6 as % of ADCA | Notes |
|---|---|---|
| Western Japan (Chugoku/Kansai) | Up to 31% | Strong founder effect |
| Germany | 13-22% | |
| United States | 12-15% | |
| South Korea | 7% | |
| United Kingdom | ~5% | Point prevalence 1.59/100,000 |
| France/Spain | 1-2% | |
The high prevalence in Western Japan, particularly around the Seto Inland Sea, is attributed to a founder effect. Global haplotype analysis suggests pathogenic expansions are associated with a common CACNA1A haplotype across populations worldwide[16](#1).
The study of Spinocerebellar Ataxia Type 6 (Sca6) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
This section highlights recent publications relevant to this disease.